News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
PCI’s Ben Dibling Provides Insight on Commercialization Strategies
Dibling explains different commercialization scenarios recommended to faculty.
Carl June Speaks to the Inquirer About the Future of CAR-T Therapy
June explains the applications of CAR-T applications beyond blood cancers.
Future mRNA Vaccines May Prevent Food and Seasonal Allergies
These advancements are paving the way for potential future treatments for seasonal and food allergies in humans.
I-Corps Graduate Serpent Robotics Wins the Eighth Annual Pennovation Accelerator Pitch Day
Serpent is formed around robotic arm technology invented by Mark Yim, PhD.
Regenxbio Showcases Promising Gene Therapy Data for Hunter Syndrome Treatment
The company reported long-term data demonstrating that its experimental treatment for Hunter syndrome, a rare genetic disorder.
GEMMABio Launches Rare Therapeutics. to Develop and Deliver Gene Therapies for Rare Diseases
Rare Therapeutics is a clinical-stage company focused on developing accessible and sustainable gene therapies for ultra-orphan diseases.
MavriX Bio Receives FDA Fast Track Designation for Angelman Syndrome Treatment
MavriX is a Penn startup company based on technology developed by James Wilson, MD, PhD.
Verismo Therapeutics Announces Clinical Trial Partnership with Miltenyi Biotec
Verismo successfully manufactured its first clinical cell product using viral vector supplied by Miltenyi Bioindustry.
Dispatch Bio Named a 2025 Startup Company to Watch by Endpoints News
The company was recognized for bringing ‘universality’ to cell therapies for solid tumors.
BlueWhale Bio Reaches Major Cell Therapy Clinical Milestone
The company aims to streamline the manufacturing process for huCART19-IL18 cells in the treatment of hematologic cancers.